Abstract:Background Colorectal carcinoma is one of the most common malignant tumors. Despite advances in therapy, mortality is still very high. The aim of this study was to evaluate the expression of paxillin in the human colon adenocarcinoma cell line SW480 and its role in cell cycle and apoptosis. We also investigated the expression of paxillin in colorectal carcinoma tissues and its relationship to clinicopathological features and survival. Methods Paxillin short hairpin RNA (shRNA) was constructed and transfected into the colon adenocarcinoma cell line SW480. The influence of paxillin shRNA on the cell cycle and cell apoptosis was analyzed by flow cytometry. Immunohistochemistry staining was used to assess the expression of paxillin and its association with the expression of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, p53 and Bcl-2 in 102 patients with primary colorectal carcinoma. Western blotting was also used to investigate the expression of paxillin. Medical records were reviewed and a clinicopathological analysis was performed. Results In vitro, the percentage of cells in S phase was (45.23 +/- 1.05)%, (43.53 +/- 1.23)%, and (36.13 +/- 0.57)% in the blank control group, negative control group, and paxillin shRNA group respectively. It was significantly decreased in the paxillin shRNA group (P=0.000). The early apoptosis index of the paxillin shRNA group (17.2 +/- 1.18%) was significantly increased compared to the control shRNA group ((13.17 +/- 1.15)%, P=0.013). Paxillin was positive in 71 (69.6%) patients, and it was found to be overexpressed in tumor tissues compared with normal adjacent tissues. Paxillin positive rate was higher in patients who are less than 50-years old (100.0% vs. 65.6%, P=0.016). Paxillin expression was associated with a high histologic grade of carcinoma (81.4% vs. 61.0%, P=0.031), a high rate of regional lymph node metastasis (22.5% vs. 13.0%, P=0.031), mesenteric artery lymph node metastasis (100.0% vs. 64.8%, P=0.008), distant metastasis (94.1% vs. 64.7%, P=0.016) and a high Tumor Node Metastasis (TNM) stage (94.1%, 73.2%, 60.0%, and 50%, P=0.030). Multivariate analyses revealed that recurrence was associated with the rate of regional lymph node metastasis (P=0.001) and paxillin expression (P=0.024). Multivariate analysis indicated that the overall survival is related to the TNM stage (P=0.000). Conclusions In vitro, paxillin may promote cell proliferation and inhibit apoptosis in SW480 cells. Paxillin may be a potential metastasis predictor, and an independent prognosis factor of recurrence. It may also be related to poor patient outcomes, but was not an independent predictor of survival.

The Role of Paxillin Aberrant Expression in Cancer and Its Potential As a Target for Cancer Therapy

Role of paxillin in colorectal carcinoma and its relationship to clinicopathological features.

Rearch Progress on the Relationship Between Mast Cells and Cancer

Increased Paxillin Expression in Prostate Cancer is Associated with Advanced Pathological Features, Lymph Node Metastases and Biochemical Recurrence

Paxillin Knockdown Suppresses Metastasis and Epithelial‑mesenchymal Transition in Colorectal Cancer Via the ERK Signalling Pathway

Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer

The Role of the PAX Genes in Renal Cell Carcinoma

The explorations of dynamic interactions of paxillin at the focal adhesions

Paxillin is Positively Correlated with the Clinicopathological Factors of Colorectal Cancer, and Knockdown of Paxillin Improves Sensitivity to Cetuximab in Colorectal Cancer Cells.

Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis

Correlationship between expression of Paxillin in bladder urothelial carcinoma and lymph node metastasis and survival prognosis

The role of Actopaxin in tumor metastasis

Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression

Pax5 Alpha Enhances the Epithelial Behavior of Human Mammary Carcinoma Cells

Role of PAX2 in breast cancer verified by bioinformatics analysis and in vitro validation

Integrins in cancer: Emerging mechanisms and therapeutic opportunities

Aberrant expression and functions of protocadherins in human malignant tumors

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer

PAX9 in Cancer Development

Does Axl have potential as a therapeutic target in pancreatic cancer?

An ULK1/2‐PXN mechanotransduction pathway suppresses breast cancer cell migration